Chapter 1 │ Page 25 References 1. World Health Organization. Cancer – key facts [Internet]. Geneva: WHO; 2025 [cited 2025 May 8]. Available from: https://www.who.int/news-room/factsheets/detail/cancer 2. National Cancer Institute. Cancer statistics. Bethesda (MD): NCI; 2025 Available: https://www.cancer.gov/about-cancer/understanding/statistics 3. Liu, B., et al., Exploring treatment options in cancer: tumor treatment strategies. Signal Transduction and Targeted Therapy, 2024. 9(1): p. 175. 4. Yalamarty, S.S.K., et al., Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). Cancers (Basel), 2023. 15(7). 5. Amaral, M.N., et al., Current Insights and Progress in the Clinical Management of Head and Neck Cancer. Cancers (Basel), 2022. 14(24). 6. Wood, L.D., et al., Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. Gastroenterology, 2022. 163(2): p. 386-402.e1. 7. Ma uid, K. and Y. Cao, Decoding the Complexity of Immune-Cancer Cell Interactions: Empowering the Future of Cancer Immunotherapy. Cancers (Basel), 2023. 15(16). 8. de Visser, K.E. and J.A. Joyce, The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell, 2023. 41(3): p. 374-403. 9. Zhang, L., et al., Targets of tumor microenvironment for potential drug development. MedComm – Oncology, 2024. 3(1): p. e68. 10. Tiwari, A., R. Trivedi, and S.-Y. Lin, Tumor microenvironment: barrier or opportunity towards e ective cancer therapy. Journal of Biomedical Science, 2022. 29(1): p. 83. 11. Wang, R., et al., The interaction of innate immune and adaptive immune system. MedComm, 2024. 5(10): p. e714. 12. Mellman, I., et al., The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity, 2023. 56(10): p. 2188-2205. 13. Kim, S.K. and S.W. Cho, The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front Pharmacol, 2022. 13: p. 868695. 14. Horton, J.D., et al., Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy. Trends Cancer, 2019. 5(4): p. 208-232. 15. Bald, T., et al., The NK cell–cancer cycle: advances and new challenges in NK cell– based immunotherapies. Nature Immunology, 2020. 21(8): p. 835-847. 16. Bila, M., et al., Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncology, 2024. 149: p. 106664. 17. Herrscher, H. and C. Robert, Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. Curr Opin Oncol, 2020. 32(2): p. 106-113. 18. Olivares-Hernández, A., et al., Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review. Ann Transl Med, 2023. 11(10): p. 354.
RkJQdWJsaXNoZXIy MTk4NDMw